DTIL
Precision BioSciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.47
+1.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 45.1M | 34.3M | 68.7M | 48.7M | 25.1M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 45.1M | 34.3M | 68.7M | 48.7M | 25.1M |
| Operating Expenses | |||||
| R&D Expense | 53.3M | 54.2M | 59.6M | 53.4M | 46.1M |
| SG&A Expense | 28.1M | 32.2M | 35.3M | 39.1M | 41.3M |
| General & Admin Expense | 28.1M | 32.2M | 35.3M | 39.1M | 41.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 81.5M | 86.4M | 94.9M | 92.5M | 87.4M |
| Cost and Expenses | 81.5M | 86.4M | 94.9M | 92.5M | 87.4M |
| Operating Income (EBIT) | (36.4M) | (52.1M) | (26.2M) | (43.7M) | (62.3M) |
| Non-Operating | |||||
| Interest Income | 3.7M | 4.2M | 6.8M | 7.7M | 3.5M |
| Interest Expense | 1.3M | 1.4M | 1.8M | 2.2M | 1.1M |
| Net Interest Income | 2.4M | 2.8M | 5.0M | 5.5M | 2.4M |
| Other Non-Op Income/Expense | (17.2M) | 5.5M | 33.3M | 1.2M | (10.6M) |
| Non-Operating Income (excl Interest) | 15.9M | (7.0M) | (35.1M) | (3.4M) | 9.5M |
| EBT (Pre-Tax Income) | (53.6M) | (46.6M) | 7.2M | (42.5M) | (72.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (52.7M) | (45.7M) | 7.2M | (61.3M) | (111.6M) |
| Earnings from Cont. Ops | (53.6M) | (46.6M) | 7.2M | (42.5M) | (72.9M) |
| Earnings from Discont. Ops | — | 885.0K | — | (18.8M) | (38.7M) |
| Bottom Line Net Income | (52.7M) | (45.7M) | 7.2M | (61.3M) | (111.6M) |
| Per Share | |||||
| Basic EPS | ($2.79) | ($3.56) | $1.05 | ($15.96) | ($38.10) |
| Diluted EPS | ($2.80) | ($3.56) | $1.04 | ($15.96) | ($38.10) |
| Revenue Per Share | $1.74 | $2.67 | $10.05 | $12.68 | $8.57 |
| Shares | |||||
| Basic Shares Outstanding | 25.9M | 12.8M | 6.8M | 3.8M | 2.9M |
| Diluted Shares Outstanding | 25.9M | 12.8M | 6.9M | 3.8M | 2.9M |
| Profitability Metrics | |||||
| EBITDA | (50.1M) | (42.4M) | 13.5M | (32.0M) | (62.8M) |
| D&A | 2.2M | 2.8M | 4.6M | 8.3M | 9.0M |
| EBIT | (52.3M) | (45.2M) | 8.9M | (40.3M) | (71.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026